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Abstract
Background—Little is known about varicella-zoster virus (VZV) susceptibility in US-bound 
refugee populations, although published data suggest that VZV seroprevalence in these refugee 
populations may be lower than US populations. We describe VZV seroprevalence in 5 U.S.-bound 
refugee groups: (1) Bhutanese in Nepal, (2) Burmese on the Thailand-Burma (Myanmar) border, 
(3) Burmese in Malaysia, (4) Iraqi in Jordan, and (5) Somali in Kenya.
Methods—Sera were tested for presence of VZV IgG antibodies among adults aged 18–45 years.
Results—Overall VZV seroprevalence was 97% across all refugee groups. VZV seroprevalence 
was also high across all age groups, with seroprevalence ranging from 92–100% for 18–26 year-
olds depending on refugee group and 93–100% for 27–45 year-olds.
Discussion—VZV seroprevalence was unexpectedly high in these 5 US-bound refugee groups, 
though may not reflect seroprevalence in other refugee groups. Additional studies are needed to 
better understand VZV seroprevalence in refugee populations over time and by region.
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BACKGROUND
Although the majority of adults born in the United States are seropositive for antibodies to 
the varicella-zoster virus (VZV) [1], refugees arriving in the United States, particularly those 
from tropical climates, may have lower VZV seropositivity rates [1, 2]. Such persons are at 
risk for VZV infection as adults, who typically develop more severe disease [2]. Every year, 
the United States offers resettlement to approximately 50,000–75,000 refugees for whom 
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repatriation to their country of origin or local integration in the host country is not a viable, 
durable solution. These refugees, representing more than 69 nationalities, are resettled from 
camps and urban locations in 92 host countries of asylum [3]. Approximately 56,000 
refugees arrived in the United States during fiscal year (FY) 2011 [3]; the largest proportion 
comprised persons from Burma (30%), Bhutan (27%), Iraq (16%), and Somalia (6%) [3].
Varicella vaccination is not typically provided in refugee camp settings or included as part 
of the national vaccine schedules in most of the countries hosting refugees. Furthermore, 
unlike immigrants, U.S.-bound refugees are not required to undergo assessment for evidence 
of VZV immunity or to receive vaccines recommended by the Advisory Committee on 
Immunization Practices (ACIP) prior to arrival in the United States [4, 5].
Few published data on VZV seroprevalence among adults in US-bound refugee groups are 
available; as such, little is known about VZV susceptibility in these populations. We 
describe VZV seroprevalence in adults in 5 U.S.-bound refugee groups using stored sera 
specimens. Data on VZV seroprevalence will be useful in guiding recommendations on 
varicella vaccination for newly arriving groups.
METHODS
Specimens for adults aged 18–45 years were obtained from the Migrant Serum Bank at the 
Centers for Disease Control and Prevention (CDC) (Atlanta, GA). US-bound refugees and 
immigrants are required to undergo medical examination overseas prior to departure to 
identify any conditions of public health concern (such as infectious tuberculosis) that would 
preclude entry into the United States [4]. The CDC Migrant Serum Bank stores de-identified 
sera remaining from blood routinely collected during this screening. Data on refugees with 
available sera are limited to age, gender, nationality, most recent camp or location of 
residence, and date of serum collection.
We selected 5 groups that represented a large proportion of refugees resettled in the United 
States in 2011 [3] and that had available sera in the CDC Migrant Serum Bank. These 
refugee groups included (1) Bhutanese from camps in Damak, Nepal, (2) Burmese from 
camps on the Thailand-Burma (Myanmar) border, (3) Burmese living in urban areas of 
Malaysia, (4) Iraqis living in urban areas of Jordan, and (5) Somali refugees living in urban 
Nairobi and in a camp in Kakuma, located 812 km northwest of Nairobi. We selected 
specimens from the most recent years of collection for each refugee group.
Detection of VZV immunoglobulin (Ig) G antibodies by VZV IgG enzyme-linked immune-
sorbent assay (ELISA) is an indicator of prior VZV infection [6]. VZV IgG may be 
detectable within the first 4 days of rash or other symptoms and up to years and even 
decades after clinical symptoms, but without active varicella symptoms, detection of VZV 
IgG antibodies is likely a reflection of prior VZV infection [7]. Serum samples were tested 
at the CDC National VZV Laboratory for VZV IgG using an in-house whole-cell ELISA 
[8]. Per CDC’s standard protocol, samples that were negative for VZV by VZV IgG ELISA 
were retested using a more sensitive glycoprotein IgG ELISA [8].
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Data were analyzed using SAS (version 9.2; SAS Institute Inc, Cary, NC). This project was 
determined by CDC not to require ethical review since it involved use of previously 
collected specimens without personally identifiable information.
RESULTS
A total of 1,105 specimens collected between 2003 and 2008 were tested [Table 1]. The 
median age of refugees tested was 30 years (18–45 years); 52% of specimens were from 
males.
Overall VZV seroprevalence was 97% across all refugee groups (range: 94–99% by refugee 
group) [Table 2]. Somali refugees in Nairobi, Kenya had the lowest VZV seroprevalence 
(94%), whereas Bhutanese refugees in Damak, Nepal and Burmese refugees in Kuala 
Lumpur, Malaysia had the highest seroprevalence (99% in both groups).
Rates of VZV IgG seropositivity were high across all age groups (range: 92–100%) [Table 
2]. VZV seroprevalence was ≥92% among 18–26 year-olds and ≥93% among ≥27 year-olds.
DISCUSSION
VZV seroprevalence was ≥90% (range 94%–99%) in all refugee groups tested, even among 
the younger adults (18–26 years). With little varicella vaccination occurring among US-
bound refugees prior to arrival, VZV seropositivity among these refugees likely resulted 
from natural disease. The VZV seroprevalence found in these 5 US-bound refugee groups 
from tropical climates was higher than other published estimates of VZV seroprevalence 
among refugee populations or populations living in tropical climates [1, 2, 9, 10]. The high 
VZV seroprevalence in groups in this study may be related to occurrence of varicella 
outbreaks in refugee camps [11]; increased likelihood of transmission due to crowded living 
conditions in the camps; or increased exposure opportunities due to migration, rather than a 
reflection of the underlying seroepidemiology in the countries of origin or residence prior to 
US-arrival. Varicella outbreaks have been reported among US-bound refugees. Between 
2004–2007, CDC responded to 19 vaccine-preventable disease outbreaks among US-bound 
refugees, including varicella [11]. Such outbreaks can lead to postponement of departure 
while affected individuals recuperate. In some circumstances, CDC has drafted specific, 
time-limited varicella vaccination recommendations for US-bound refugee groups affected 
by varicella outbreaks.
One study of Somali refugees who resettled in Minnesota in 1998 found similar findings to 
seroprevalence rates as in this study, with a VZV-seropositivity of 94% among 18–29 year-
olds and 95% seropositive among ≥30 year-olds [12]. However, other previous studies 
reported lower rates of VZV seropositivity among resettled refugee populations. A study of 
58 Burmese refugees from Thailand aged ≥5 years arriving in Canada in 2006 found 88% 
were VZV-seropositive [10]. In a study of several refugee groups tested who were seen for 
medical evaluation in 2000–2002, VZV seroprevalence ranged from 70 to 91%, depending 
on region of origin, with VZV seroprevalence of 71–75% among those from Somalia/East 
Africa, Afghanistan/Iraq/Iran, and Asia [9]. These findings of lower seroprevalence in these 
refugee groups is consistent with findings of lower VZV seroprevalence in tropical climates 
Leung et al. Page 3













compared with adults in temperate regions [1, 2]. Some proposed explanations for 
differences in epidemiology are potential reduction in survival time or transmissibility of the 
virus in warmer climates, less opportunity for exposure in rural areas, competition with other 
viral pathogens, or differences in agent, host, and environmental factors [1].
Our study had several limitations. VZV seroprevalence rates in refugee populations may 
change over time depending on the occurrence of outbreaks and, in situations where 
refugees reside in camps, on camp composition, as populations may be dynamic. It is not 
clear the extent to which the seroepidemiology we report reflects that of the refugees’ 
countries of origin, or the location at the time of testing prior to US-arrival. Finally, we were 
unable to evaluate the VZV seroprevalence of children in these refugee groups since sera 
from children ≤15 years of age are infrequently collected during the required overseas 
medical examination.
CONCLUSIONS
Although we reported high VZV seroprevalence in these 5 US-bound refugee populations, 
data from other studies suggest that there may be a proportion of adult refugees who are 
susceptible to varicella, and at increased risk of severe disease [1]. Additional studies are 
needed to assess current VZV seroprevalence in refugee populations to understand their 
susceptibility to varicella and need for vaccination once resettled in the United States. In the 
meantime, providers who care for refugees should be aware that VZV epidemiology in these 
groups may differ from that seen in US-born persons. Providers should assess for evidence 
of immunity to varicella [13] (documentation of age-appropriate vaccination with varicella 
vaccine, laboratory evidence of immunity or laboratory confirmation of disease, birth in the 
United States before 1980, or diagnosis or verification by a health-care provider of a history 
of varicella or herpes zoster disease) and other vaccine-preventable diseases and vaccinate 
according to ACIP recommendations [5]. Refugees are a heterogeneous group with various 
backgrounds and health profiles; therefore, public health messages targeted for refugees 
should consider differences in language, culture, customs, and health needs.
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Table 2
VZV Seroprevalence by Refugee and Age Group, 2003–2008
Age Group (years) # VZV IgG Positive Specimens/# Total Specimens % VZV IgG Positive Specimens (95% CI)
Bhutanese refugees in Damak-area camps, Nepal
All Ages 99/100 99 (95–100)
18–26 42/42 100 (92–100)
27–35 25/26 96 (80–100)
36–45 32/32 100 (89–100)
Burmese refugees in Thailand-Burma (Myanmar) border
All Ages 279/288 97 (95–99)
18–26 106/110 96 (93–100)
27–35 90/95 95 (90–99)
36–45 83/83 100 (96–100)
Burmese refugees in Kuala Lumpur, Malaysia
All Ages 140/142 99 (95–100)
18–26 48/48 100 (93–100)
27–35 74/76 97 (91–100)
36–45 18/18 100 (81–100)
Iraqi refugees in Amman, Jordan
All Ages 277/287 97 (94–98)
18–26 89/97 92 (84–96)
27–35 105/106 99 (95–100)
36–45 83/84 99 (94–100)
Somali refugees in Kakuma, Kenya
All Ages 197/206 96 (92–98)
18–26 66/69 96 (88–99)
27–35 64/69 93 (84–98)
36–45 67/68 99 (92–100)
Somali refugees in Nairobi, Kenya
All Ages 77/82 94 (86–98)
18–26 52/56 93 (83–98)
27–35 6/6 100 (54–100)
36–45 19/20 95 (75–100)
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